Takeda CEO facing pressure amid dismal profits — 4 key notes

Takeda Pharmaceuticals President and CEO Christophe Weber could face increased scrutiny after the retirement of Chairman Yasuchika Hasegawa, Biospace.com reports. 

Here's what you should know:

1. Mr. Hasegawa was supposed to assume a corporate councilor position following his retirement, but the company's stakeholders rejected the appointment after Takeda posted "dismal" earnings.

2. Mr. Hasegawa was often advocated for Mr. Weber according to the Nikkei Asian Review.

3. Mr. Weber is facing criticism over Takeda's falling profitability, recent acquisitions and decreased research-and-development efforts.

4. Takeda has pivoted towards acquiring drug candidates through large price tag acquisitions instead of developing them in house.

More articles on gastroenterology:
FDA accepts application for Salix Pharmaceuticals' new bowel cleansing preparation — 4 key notes
Potentially infected scope at Kaiser Permanente facility puts 23 at risk & more: 4 GI practices in the news
GI center to know: The Digestive Health Institute of Montana

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months